Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30907933.
- Also identified by DOI 10.1001/jama.2019.2990 and PMC identifier 6487544.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.
Medical subject headings
- Biosimilar Pharmaceuticals
- Drug Utilization
- Insulin, Long-Acting
- Insurance, Health, Reimbursement
- Medicaid